IQANOVA unites mechanistic pharmacology — QSP, PBPK and PBBM — with AI surrogates, living SBML models, EHMN metabolic backbones and regulatory-ready documentation to cut timelines and de-risk decisions.
IQANOVA scientific story.
A practical, context-of-use-driven review for validating AI-QSP surrogates across endpoint accuracy, trajectory fidelity, uncertainty, biological plausibility, distributional agreement and computational efficiency.
Read via DOI →A thermodynamically refined, SBML-standardised human metabolic network for genome-scale analysis and QSP integration, designed for reproducibility, interoperability and multi-layer modelling.
Read article →A license-aware AI-QSP integration framework linking EHMN2026 with TRANSFAC, TRANSPATH and HumanPSD for diagnostic-metabolite interpretation and controlled model-building workflows.
Read article →ATLAS turns mechanistic models into living, versioned, regulatory-aware assets — from open SBML blueprints to validated decision layers and quarterly model refreshes.
Explore ATLAS →SBML, model cards, release notes and public documentation where redistribution is permitted.
Fitted, validated, regulator-aware models, reports, dashboards and custom scenarios.
Evidence retrieval, curation, parameter updates, re-validation and change logs.
QSP, PBPK, PBBM and GEM models grounded in pathways, receptors, PK/PD and disease biology.
Surrogate models, Bayesian updating, neural ODEs and virtual population simulation at scale.
Interoperable model exchange, machine-readable outputs, versioning, citations and audit trails.
Traceability, context-of-use statements, validation reports and claim-control gates.
Thermodynamically refined SBML L3V2/FBC2 genome-scale human metabolic network.
License-aware layerDiagnostic metabolite interpretation with regulatory, signalling and disease/drug context.
ATLAS modelsCAR-T, GLP-1, EPO/ESA, Pompe, ASMD, AIG-VHT, asthma, aspirin, anaesthetics and more.
Custom buildUpload or discuss a model for IQANOVA review, extension, SBML conversion and V&V.
AI-assisted reconstruction, literature extraction, parameter governance and documentation reduce repeated manual work.
Reusable templates, SBML assets and surrogate workflows scale modelling across portfolios instead of isolated expert builds.
Context-of-use validation, stress tests and transparent limitations make model outputs safer for clinical and regulatory discussions.
Co-develop models, request EHMN access, integrate ATLAS outputs, or set up a confidential briefing.